Assetmark Inc. boosted its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 12.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 152,810 shares of the medical equipment provider's stock after acquiring an additional 16,986 shares during the quarter. Assetmark Inc.'s holdings in Boston Scientific were worth $12,806,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds have also bought and sold shares of BSX. Eagle Bay Advisors LLC raised its holdings in Boston Scientific by 542.1% during the 1st quarter. Eagle Bay Advisors LLC now owns 366 shares of the medical equipment provider's stock valued at $25,000 after buying an additional 309 shares during the last quarter. First Foundation Advisors purchased a new position in shares of Boston Scientific in the first quarter valued at about $25,000. Triad Wealth Partners LLC bought a new position in shares of Boston Scientific during the second quarter valued at about $26,000. Values First Advisors Inc. purchased a new stake in shares of Boston Scientific during the third quarter worth about $28,000. Finally, Andra AP fonden bought a new stake in shares of Boston Scientific in the second quarter worth about $29,000. 89.07% of the stock is currently owned by institutional investors.
In related news, EVP Wendy Carruthers sold 6,983 shares of the firm's stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $81.70, for a total value of $570,511.10. Following the transaction, the executive vice president now directly owns 37,468 shares of the company's stock, valued at approximately $3,061,135.60. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, EVP Wendy Carruthers sold 6,983 shares of the firm's stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $81.70, for a total value of $570,511.10. Following the transaction, the executive vice president now owns 37,468 shares of the company's stock, valued at $3,061,135.60. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 132,527 shares of the business's stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $85.00, for a total value of $11,264,795.00. Following the transaction, the executive vice president now owns 160,467 shares of the company's stock, valued at approximately $13,639,695. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 309,270 shares of company stock worth $26,196,718 in the last 90 days. 0.50% of the stock is currently owned by insiders.
Shares of NYSE:BSX opened at $88.25 on Monday. The business has a 50-day simple moving average of $84.61 and a two-hundred day simple moving average of $79.00. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.14 and a current ratio of 1.48. The firm has a market cap of $130.07 billion, a price-to-earnings ratio of 72.93, a price-to-earnings-growth ratio of 2.55 and a beta of 0.79. Boston Scientific Co. has a fifty-two week low of $50.84 and a fifty-two week high of $88.94.
Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 EPS for the quarter, topping analysts' consensus estimates of $0.59 by $0.04. The business had revenue of $4.21 billion during the quarter, compared to the consensus estimate of $4.04 billion. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The firm's revenue was up 19.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.50 EPS. On average, analysts expect that Boston Scientific Co. will post 2.46 earnings per share for the current year.
Several research firms have recently issued reports on BSX. Wells Fargo & Company boosted their target price on Boston Scientific from $87.00 to $98.00 and gave the company an "overweight" rating in a research note on Thursday, October 24th. Canaccord Genuity Group upped their price objective on shares of Boston Scientific from $88.00 to $98.00 and gave the stock a "buy" rating in a report on Monday, October 21st. Bank of America boosted their price target on shares of Boston Scientific from $90.00 to $100.00 and gave the company a "buy" rating in a research report on Tuesday, October 22nd. Deutsche Bank Aktiengesellschaft lifted their price objective on Boston Scientific from $73.00 to $78.00 and gave the company a "hold" rating in a research report on Thursday, July 25th. Finally, Mizuho increased their target price on Boston Scientific from $100.00 to $110.00 and gave the stock an "outperform" rating in a research report on Thursday, October 24th. Four equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $93.39.
Check Out Our Latest Stock Analysis on Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Boston Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.
While Boston Scientific currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.